Using the dCas9-KRAB system to repress gene expression in hiPSC-derived NGN2 neurons

We describe a CRISPR inhibition (CRISPRi) protocol to repress endogenous gene expression (e.g., ATP6V1A) in human induced pluripotent stem cell-derived NGN2-induced glutamatergic neurons. CRISPRi enables efficient and precise gene repression of one or multiple target genes via delivering gRNA(s) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Aiqun, Cartwright, Samuel, Yu, Alex, Ho, Seok-Man, Schrode, Nadine, Deans, P.J. Michael, Matos, Marliette R., Garcia, Meilin Fernandez, Townsley, Kayla G., Zhang, Bin, Brennand, Kristen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188621/
https://www.ncbi.nlm.nih.gov/pubmed/34151300
http://dx.doi.org/10.1016/j.xpro.2021.100580
Descripción
Sumario:We describe a CRISPR inhibition (CRISPRi) protocol to repress endogenous gene expression (e.g., ATP6V1A) in human induced pluripotent stem cell-derived NGN2-induced glutamatergic neurons. CRISPRi enables efficient and precise gene repression of one or multiple target genes via delivering gRNA(s) to direct a dCas9-KRAB fusion protein to the gene(s) of interest. This protocol can also be adapted for gene activation and high-throughput gene manipulation, allowing assessment of the transcriptomic and phenotypic impact of candidate gene(s) associated with neurodevelopment or brain disease. For complete details on the use and execution of this protocol, please refer to Ho et al. (2017) and Wang et al. (2021).

Ejemplares similares